BiondVax Pharmaceuticals Ltd.
NASDAQ: BVXV0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Amir Reichman
- Employees
- 33
- Headquarters
- Jerusalem, Israel
- IPO year
- 2015
- Market cap
- $5.0M
- Website
- https://www.biondvax.com
Loading BVXV…
Loading profile data…Frequently asked questions about BVXV
What does BiondVax Pharmaceuticals Ltd. (BVXV) do?
BiondVax Pharmaceuticals Ltd. is an Israeli-based biopharmaceutical company currently in its development stage. Its core mission involves the research, production, and market introduction of therapeutic products designed for the prevention and treatment of a range of infectious and other medical conditions. The company has established strategic...
Where does BVXV trade?
BiondVax Pharmaceuticals Ltd. (BVXV) trades on the NASDAQ Capital Market.
What sector is BVXV in?
BiondVax Pharmaceuticals Ltd. (BVXV) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of BiondVax Pharmaceuticals Ltd.?
Amir Reichman is the chief executive officer of BiondVax Pharmaceuticals Ltd. (BVXV).
Where is BiondVax Pharmaceuticals Ltd. headquartered?
BiondVax Pharmaceuticals Ltd. is headquartered in Israel.
Does BVXV pay a dividend?
BiondVax Pharmaceuticals Ltd. (BVXV) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did BVXV go public?
BiondVax Pharmaceuticals Ltd. (BVXV) completed its initial public offering in 2015.
Is BVXV an ADR?
Yes — BVXV is an American Depositary Receipt; its underlying shares trade on a non-US exchange. BiondVax Pharmaceuticals Ltd. reporting and dividends follow the underlying issuer.